WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 563502
Description: BVT948 is a protein tyrosine phosphatases (PTP) inhibitor (IC50 = 0.09 - 1.7 μM). BVT948 inhibits NF-κB activation by suppressing IκBα degradation and the nuclear translocation of NF-κB in TPA-treated MCF-7 cells. BVT948 didn’t block TPA-induced AP-1 activation in MCF-7 cells. BVT948 blocks MMP-9 expression of breast cancer cells by inhibiting the TPA-stimulated NF-κB pathway.
MedKoo Cat#: 563502
Chemical Formula: C14H11NO3
Exact Mass: 241.0739
Molecular Weight: 241.24
Elemental Analysis: C, 69.70; H, 4.60; N, 5.81; O, 19.90
Synonym: BVT948; BVT-948; BVT 948; SPS8I3; SPS-8I3; SPS 8I3;
IUPAC/Chemical Name: 4-hydroxy-3,3-dimethyl-2H-benzo[g]indole-2,5(3H)-dione
InChi Key: BAQXWJQSUXZVIP-UHFFFAOYSA-N
InChi Code: InChI=1S/C14H11NO3/c1-14(2)9-10(15-13(14)18)7-5-3-4-6-8(7)11(16)12(9)17/h3-6,17H,1-2H3
SMILES Code: O=C(C(C)(C)C1=C2O)N=C1C3=CC=CC=C3C2=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
The following data is based on the product molecular weight 241.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Chen W, Ennes HS, McRoberts JA, Marvizón JC. Mechanisms of μ-opioid receptor inhibition of NMDA receptor-induced substance P release in the rat spinal cord. Neuropharmacology. 2018 Jan;128:255-268. doi: 10.1016/j.neuropharm.2017.10.014. Epub 2017 Oct 16. PubMed PMID: 29042318; PubMed Central PMCID: PMC5726399.
2: Mironova GY, Avdonin PP, Goncharov NV, Jenkins RO, Avdonin PV. Inhibition of protein tyrosine phosphatases unmasks vasoconstriction and potentiates calcium signaling in rat aorta smooth muscle cells in response to an agonist of 5-HT2B receptors BW723C86. Biochem Biophys Res Commun. 2017 Jan 29;483(1):700-705. doi: 10.1016/j.bbrc.2016.12.079. Epub 2016 Dec 13. PubMed PMID: 27986565.
3: Blum G, Ibáñez G, Rao X, Shum D, Radu C, Djaballah H, Rice JC, Luo M. Small-molecule inhibitors of SETD8 with cellular activity. ACS Chem Biol. 2014 Nov 21;9(11):2471-8. doi: 10.1021/cb500515r. Epub 2014 Sep 3. PubMed PMID: 25137013; PubMed Central PMCID: PMC4245162.
4: Hwang BM, Chae HS, Jeong YJ, Lee YR, Noh EM, Youn HZ, Jung SH, Yu HN, Chung EY, Kim JS. Protein tyrosine phosphatase controls breast cancer invasion through the expression of matrix metalloproteinase-9. BMB Rep. 2013 Nov;46(11):533-8. PubMed PMID: 24152909; PubMed Central PMCID: PMC4133842.
5: Chen W, Zhang G, Marvizón JC. NMDA receptors in primary afferents require phosphorylation by Src family kinases to induce substance P release in the rat spinal cord. Neuroscience. 2010 Mar 31;166(3):924-34. doi: 10.1016/j.neuroscience.2010.01.009. Epub 2010 Jan 13. PubMed PMID: 20074620; PubMed Central PMCID: PMC2837134.